USFDA observations to Biocon's Malaysia facility not serious, say analysts
Updated : March 04, 2020 02:00 PM IST
At the conclusion of the inspection, the agency had issued a Form 483 with 3 observations.
The observations received by the Biocon from the US drug regulator for its Malaysia plant are procedural and not serious, analysts said.
Analysts believe this is a positive development for the company and it does not look like anything as serious as data integrity.